Lisanti Capital Growth LLC lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 25.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,470 shares of the biotechnology company's stock after selling 59,565 shares during the quarter. Lisanti Capital Growth LLC owned 0.07% of ADMA Biologics worth $3,009,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of ADMA. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock worth $13,171,000 after purchasing an additional 80,400 shares during the period. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics during the third quarter worth about $61,858,000. EWG Elevate Inc. acquired a new position in shares of ADMA Biologics during the fourth quarter worth about $480,000. Citigroup Inc. increased its stake in shares of ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock worth $7,741,000 after buying an additional 277,138 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after acquiring an additional 2,613,482 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
View Our Latest Research Report on ADMA
ADMA Biologics Stock Up 4.5 %
Shares of NASDAQ ADMA traded up $0.74 during midday trading on Tuesday, hitting $17.35. 2,549,565 shares of the company's stock were exchanged, compared to its average volume of 3,321,916. The firm's fifty day simple moving average is $16.64 and its 200-day simple moving average is $17.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a market cap of $4.10 billion, a PE ratio of 61.96 and a beta of 0.60. ADMA Biologics, Inc. has a twelve month low of $5.88 and a twelve month high of $23.64.
ADMA Biologics Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
